Meta Information
ID:omega-7
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Omega-7 fatty acids may possess mild antiplatelet properties, which could add to the effects of anticoagulant or antiplatelet medications, theoretically increasing the risk of bleeding or bruising.
Actionable advice:
It is important to consult a doctor before combining; it is a good idea to monitor for signs of increased bleeding or bruising.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Some botanicals may cause bleeding events when taken alone (e.g., garlic and Ginkgo biloba) and may have anticoagulant, antiplatelet, and/or fibrinolytic properties.
Label source:
Action type:
monitor
Target id:
/class/antidiabetic-medications
Target name:
Diabetes Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Omega-7s, particularly palmitoleic acid, may improve insulin sensitivity and lower blood glucose levels, potentially enhancing the effects of diabetes medications and increasing the risk of hypoglycemia (low blood sugar).
Actionable advice:
Blood glucose levels are best monitored closely when starting or adjusting the dose, and it is important to consult a healthcare provider.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Label source:
Action type:
monitor
Target id:
/procedure/surgery
Target name:
Upcoming Surgery
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
336
Hours after target:
null
Description:
The potential for increased bleeding risk due to omega-7's possible antiplatelet effects necessitates stopping the supplement well before any surgical procedure to allow platelet function to normalize.
Actionable advice:
Use should be discontinued at least 2 weeks prior to any scheduled surgery, and it is important to let a surgeon know.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Instead, a clear decrease in the rate of adenosine-5'-diphosphate-induced platelet aggregation and maximum aggregation were found.
Label source:
PubMed: Sea buckthorn berry oil inhibits platelet aggregation. (PMID 11120446)
Action type:
avoid
Target id:
/class/bile-acid-sequestrants
Target name:
Bile Acid Sequestrants
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
4
Description:
Bile acid sequestrants (e.g., cholestyramine) can bind to fatty acids and fat-soluble nutrients in the gut, preventing their absorption and reducing the effectiveness of the supplement.
Actionable advice:
Omega-7 is best taken at least 1 hour before or 4 hours after a bile acid sequestrant.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Because cholestyramine binds bile acids, QUESTRAN may interfere with normal fat digestion
and absorption and thus may prevent absorption of fat-soluble vitamins such as A, D, E and
K.
Label source:
Action type:
separate
Target id:
/intervention/orlistat
Target name:
Orlistat (Fat Absorption Inhibitor)
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
Orlistat works by blocking the absorption of dietary fats, including supplemental fatty acids like omega-7, which would render the supplement ineffective if taken together.
Actionable advice:
The omega-7 dose and orlistat should be separated by at least 2 hours.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
11 DESCRIPTION
11 DESCRIPTION XENICAL (orlistat) is a gastrointestinal lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats.
Label source:
Action type:
separate
Target id:
/class/statins
Target name:
Statins (HMG-CoA Reductase Inhibitors)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Omega-7s may help lower triglycerides and C-reactive protein (CRP), complementing the lipid-lowering and anti-inflammatory actions of statin medications.
Actionable advice:
May be taken together to support cardiovascular health; inform your doctor to monitor lipid panels.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Drug Interactions
Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter.
Label source:
Action type:
monitor
Target id:
/class/glucose-lowering-supplements
Target name:
Glucose-Lowering Supplements
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Combining omega-7s with other supplements that lower blood sugar (like berberine or alpha-lipoic acid) may have an additive effect, increasing the risk of hypoglycemia.
Actionable advice:
Some caution when combining with other glucose-lowering supplements may help, along with watching for symptoms of low blood sugar.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
higher POA levels in humans are correlated with better insulin sensitivity, an improved lipid profile, and a lower incidence of type-2 diabetes
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/38313838/
Action type:
monitor
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Some evidence suggests fatty acids can have a modest blood pressure-lowering effect, which could be additive with antihypertensive medications, potentially leading to hypotension (low blood pressure).
Actionable advice:
It is a good idea to check blood pressure when starting or changing the dose, especially while on blood pressure medication.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Apart from marine fatty acids which have mostly been significantly associated with clinically modest blood pressure-lowering, the effects of other dietary fatty acids are inconsistent or clinically minor.
Label source:
PubMed: Dietary Fat and Blood Pressure. (PMID 30747320)
Action type:
monitor
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The safety of high-dose omega-7 supplementation during pregnancy has not been established, and its effects on fetal development are unknown.
Actionable advice:
Supplementation is best avoided during pregnancy unless specifically advised by an obstetrician.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
NatMed Pro Monograph: Sea Buckthorn
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is unknown if supplemental omega-7 fatty acids are excreted into breast milk in significant amounts or what their effects on a nursing infant might be.
Actionable advice:
Supplementation is best avoided while breastfeeding due to a lack of safety data.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
NatMed Pro Monograph: Sea Buckthorn
Action type:
avoid
Target id:
/biomarker/lipid-panel
Target name:
Lipid Panel
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Omega-7 supplementation is intended to beneficially alter lipid profiles, often by reducing triglycerides and increasing HDL-C, which will be reflected in lab results.
Actionable advice:
It is generally best to let a physician know about omega-7s use when interpreting lipid panel results.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
monitor
Target id:
/biomarker/hs-crp
Target name:
hs-CRP
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The anti-inflammatory properties of palmitoleic acid can lead to a reduction in high-sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation.
Actionable advice:
Potential reductions in hs-CRP levels may occur, which may be worth considering when tracking inflammation.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
At 30 days, there were significant mean (95% confidence interval [CI]) reductions in CRP (-1.9 [-2.3 to -1.4] mg/L)... These changes equated to 44%, 15%, and 8% reductions in CRP, triglyceride, and LDL respectively
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/25499944/
Action type:
monitor
Target id:
/biomarker/hemoglobin-a1c
Target name:
Hemoglobin A1c
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
By improving insulin sensitivity, omega-7s may lead to lower fasting glucose and subsequently lower HbA1c levels over time.
Actionable advice:
Regular monitoring of glucose and HbA1c is recommended to track therapeutic effects, especially in pre-diabetes or diabetes.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
higher POA levels in humans are correlated with better insulin sensitivity, an improved lipid profile, and a lower incidence of type-2 diabetes and cardiovascular pathologies
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/38313838/
Action type:
monitor